Rossari Biotech profit and loss

Latest FY26
Revenue
₹2,396cr+15.2% on FY25
EBITDA
₹286cr+7.9% on FY25
Net profit
₹149cr+9.4% on FY25
EPS
₹26.95+9.3% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,6612,3962,0801,8311,656
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
23.422.44.07.45.5
2,6852,4192,0841,8381,661
Expenses
1,8521,6041,3001,2301,079
67.593.4165127105
−55.3−28.4−31.1−63.5−12.6
16715513210398.6
36.428.517.819.422.3
98.979.167.160.462.9
316287250184163
2,4832,2181,9001,6611,518
314286265250223
215207198189160
Profit
202201184177143
202201184177143
57.661.359.155.849.1
−6.6−8.0−10.3−8.9−12.2
50.953.348.846.937.0
1.81.91.00.21.0
153149136131107
151147135131106
1.50.1−1.00.00.3
154149135131108
153149136131—
Per share
₹27.58₹26.95₹24.66₹23.67₹19.46
₹27.55₹26.93₹24.63₹23.62₹19.38
Other comprehensive income — detail
1.50.1−1.0——
0.90.2−1.30.00.4
0.20.0−0.3——
———0.00.1
1.0−0.1———
0.2−0.00.1——
154149135131108
Per share — as-filed variants
₹27.58₹26.95₹24.66₹23.67₹19.46
₹27.55₹26.93₹24.63₹23.62₹19.38
Derived — gross profit (revenue − materials − purchases − Δ inventories)
797728647537485
29.9%30.4%31.1%29.3%29.3%
Adjusted (ex-exceptional items) — derived
202201184177143
153149136131107
₹27.58₹26.95₹24.66₹23.67₹19.46
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ROSSARI₹407.60

Rossari Biotech Limited

· Chemicals
AnnualQuarterly₹ CrorePeersNOCILHSCLNAVINFLUORDDEVPLSTIKCHEMPLASTSTATACHEMAARTIINDJGCHEMMcap ₹2,257 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue from Operations1,655.91,830.62,080.32,396.42,661.3
Other Income5.57.44.022.423.4
Total Income1,661.41,838.02,084.32,418.72,684.7
Expenses
+ Cost of Materials Consumed1,079.11,229.91,299.61,603.71,852.4
+ Purchases of Stock-in-Trade104.9127.1164.893.467.5
+ Changes in Inventories-12.6-63.5-31.1-28.4-55.3
+ Employee Benefit Expense98.6103.1132.3154.7167.1
+ Finance Costs22.319.417.828.536.4
+ Depreciation & Amortisation62.960.467.179.198.9
+ Other Expenses162.9184.1249.6287.0315.8
Total Expenses1,518.11,660.61,900.12,218.12,482.8
EBITDA223.0249.8265.1285.9313.7
EBIT160.1189.4198.0206.8214.9
Profit
PBT before Exceptional Items143.3177.4184.2200.6201.8
Pretax Income143.3177.4184.2200.6201.8
+ Current Tax49.155.859.161.357.6
+ Deferred Tax-12.2-8.9-10.3-8.0-6.6
Tax Expense37.046.948.853.350.9
+ Share of Associates & JVs1.00.21.01.91.8
Net Income107.3130.7136.4149.2152.7
+ Net Income — Continuing Ops106.3130.5135.4147.3150.9
+ Other Comprehensive Income0.30.0-1.00.11.5
Total Comprehensive Income107.6130.7135.4149.3154.2
Net Income to Common—130.7136.4149.2152.7
Per Share
Basic EPS19.4623.6724.6626.9527.58
Diluted EPS19.3823.6224.6326.9327.55
Other Comprehensive Income — detail
+ Other Comprehensive Income——-1.00.11.5
+ Items NOT to be Reclassified to P&L0.40.0-1.30.20.9
+ Tax on Items NOT to be Reclassified——-0.30.00.2
+ Tax on Items NOT to be Reclassified — alt tag0.10.0———
+ Items to be Reclassified to P&L———-0.11.0
+ Tax on Items to be Reclassified——0.1-0.00.2
Comprehensive Income — Owners of Parent107.6130.7135.4149.3154.2
Per Share — as-filed variants
Basic EPS — Continuing Operations19.4623.6724.6626.9527.58
Diluted EPS — Continuing Operations19.3823.6224.6326.9327.55
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit484.6537.0647.0727.6796.6
Gross Margin %29.2629.3431.1030.3629.93
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)143.3177.4184.2200.6201.8
Net Income Adj (tax-effected)107.3130.7136.4149.2152.7
EPS Adj19.4623.6724.6626.9527.58
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value—2.002.002.002.00
Paid Up Equity Capital11.011.011.111.111.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.